The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.

Researchers at the Leibniz Institute for Food Systems Biology at the Technical University of Munich have for the first time investigated how protein structures derived from fava beans affect a ...

Why is this stock ending the week on a high? Let's see what is getting investors excited. The post Guess which ASX 200 ...

These shares are ending the week positively. But why? The post Why Clarity, Genesis Energy, IGO, and Wesfarmers shares are charging higher appeared first on The Motley Fool Australia.

Krystal K. Haase, a professor in the Jerry H. Hodge School of Pharmacy and the school’s Regional Dean at Amarillo, was among ...

and/or concentration The event will feature concurrent Technical Breakout Sessions highlighting use of membrane technology for: Dairy—innovations and research findings, including for processing ...

Air Products (NYSE: APD) today reported preliminary voting results from its 2025 Annual Meeting of Shareholders ("Annual Meeting") held on.

Investment analysts at Zacks Research lifted their Q3 2025 earnings per share (EPS) estimates for Pentair in a research note ...

Finally, diaphragm pumps are durable and require little to no maintenance. These pumps are built to last, even in harsh ...

‘Jonny is probably the most stubborn bastard you’ll ever meet.’ Not the voice of a sworn enemy, there, but Jonny Davies’ coach, Tommy Trees. ‘Once he puts his mind to something, he’s gonna get it done ...

For the almost 520,000 Americans who will undergo treatment this year, the process leaves little room for a full life. An innovative new device could change everything.